Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile

被引:18
作者
Silvestri, Romano [1 ]
Ligresti, Alessia [2 ]
La Regina, Giuseppe [1 ]
Piscitelli, Francesco [1 ]
Gatti, Valerio [1 ]
Brizzi, Antonella [3 ]
Pasquini, Serena [3 ]
Lavecchia, Antonio [4 ]
Allara, Marco [2 ]
Fantini, Noemi [5 ]
Carai, Mauro Antonio Maria [5 ]
Novellino, Ettore [4 ]
Colombo, Giancarlo [5 ]
Di Marzo, Vincenzo [2 ]
Corelli, Federico [3 ]
机构
[1] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Fdn Cenci Bolognetti, Ist Pasteur, I-00185 Rome, Italy
[2] CNR, Ist Chim Biomol, I-80078 Naples, Italy
[3] Univ Siena, Polo Sci Univ San Miniato, Dipartimento Farmacochim Tecnol, I-53100 Siena, Italy
[4] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[5] CNR, Ist Neurosci, I-09126 Cagliari, Italy
关键词
Cannabinoid; Human recombinant CB receptor type 1; Pyrrole bioisoteres; Structure-activity relationships; Molecular modeling; ENDOCANNABINOID SYSTEM; INVERSE AGONISTS; CB1; RECEPTOR; OBESITY; POTENT; HYDROCHLORIDE; ANTAGONIST; DISCOVERY; TARGETS;
D O I
10.1016/j.bmc.2009.06.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
New substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides were synthesized by replacing the 2,4-dichlorobenzyl and cyclohexyl moieties at the 3-carboxamide nitrogen of the previously reported CB1 receptor antagonists/inverse agonists 4 and 5. Several ligands showed potent affinity for the hCB(1) receptor, with K-i concentrations comparable to the reference compounds 1, 4 and 5, and exhibited CB1 selectivity comparable to 1 and 2. Docking experiments and molecular dynamics (MD) simulations explained the potent hCB1 binding affinity of compounds 31 and 37. According to our previous studies, 31 and 37 formed a H-bond with K3.28(192), which accounted for the high affinity for the receptor inactive state and the inverse agonist activity. The finding of inhibition of food intake following their acute administration to rats, supported the concept that the CB1 selective compounds 4 and 52 act as antagonists/inverse agonists. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5549 / 5564
页数:16
相关论文
共 48 条
  • [1] [Anonymous], 2005, MOL OP ENV MOE VERS
  • [2] The endocannabinoid system and multiple sclerosis
    Baker, David
    Pryce, Gareth
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (23) : 2326 - 2336
  • [3] Ballesteros J. A., 1995, METH NEUROSCI, P366, DOI [DOI 10.1016/S1043-9471, DOI 10.1016/S1043-9471(05)80049-7]
  • [4] Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases
    Bellocchio, Luigi
    Mancini, Giacomo
    Vicennati, Valentina
    Pasquali, Renato
    Pagotto, Uberto
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2006, 6 (06) : 586 - 591
  • [5] Endocannabinoids in endocrine and related tumours
    Bifulco, Maurizio
    Malfitano, Anna Maria
    Pisanti, Simona
    Laezza, Chiara
    [J]. ENDOCRINE-RELATED CANCER, 2008, 15 (02) : 391 - 408
  • [6] Bifulco M, 2007, ONCOL REP, V17, P813
  • [7] The endocannabinoid system in amyotrophic lateral sclerosis
    Bilsland, Lynsey G.
    Greensmith, Linda
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (23) : 2306 - 2316
  • [8] The role of the endocannabinoid system in Alzheimer's disease: Facts and hypotheses
    Bisogno, Tiziana
    Di Marzo, Vincenzo
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (23) : 2299 - 2305
  • [9] Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors
    Brizzi, A
    Brizzi, V
    Cascio, MG
    Bisogno, T
    Sirianni, R
    Di Marzo, V
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) : 7343 - 7350
  • [10] Case D.A., 2006, AMBER 9